<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00988013</url>
  </required_header>
  <id_info>
    <org_study_id>2009-0251</org_study_id>
    <nct_id>NCT00988013</nct_id>
  </id_info>
  <brief_title>Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies</brief_title>
  <acronym>IM-TMI</acronym>
  <official_title>A Phase I Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Illinois at Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I study using Intensity Modulated Total Marrow Irradiation (IM-TMI) in&#xD;
      addition to a chemotherapy regimen in preparation for an allogeneic stem cell transplant for&#xD;
      advanced hematologic malignancies such as acute myeloid or lymphoblastic leukemia, high grade&#xD;
      non Hodgkin's or Hodgkin's lymphoma, chronic myelogenous leukemia, and plasma cell leukemia.&#xD;
      Because the subjects participating in this study have a disease that is severe and has a high&#xD;
      risk of relapse even after transplant, the investigators propose to use a chemotherapy&#xD;
      regimen (fludarabine/busulfan), the name for the combination of chemotherapy drugs that is&#xD;
      given to patients prior to transplantation of the donor stem cells, along with intensity&#xD;
      modulated radiation (IM-TMI) to the bone marrow. Total body irradiation (TBI) in conjunction&#xD;
      with chemotherapy is a standard of care as a pre-conditioning regimen prior to bone marrow&#xD;
      transplant (BMT) in patients with hematologic malignancies. However, TBI can cause severe&#xD;
      side effects due to irradiation of organs such as the lenses of the eye, whole brain, lungs,&#xD;
      liver, kidneys, heart, small bowel and oral cavity. IM-TMI allows for the delivery of&#xD;
      adequate doses of radiation to the bone marrow while sparing other organs and therefore&#xD;
      limiting radiation side effects. The irradiation, along with receiving the chemotherapy drugs&#xD;
      will suppress the subject's immune system and kill off tumor cells, but will also intensify&#xD;
      the effect of the conditioning regimen thus allowing the bone marrow transplantation to have&#xD;
      a greater chance of being successful.&#xD;
&#xD;
      No investigational drugs are used in this study. The investigational part of this study is&#xD;
      the use of intensity modulated total marrow irradiation instead of conventional radiation.&#xD;
      IMTMI can deliver 99% of the prescribed treatment to the targeted bones and reduce the doses&#xD;
      of radiation to surrounding organs, as received in conventional TBI, by 29% to 65%.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Dose escalation of total marrow irradiation prior to stem cell transplantation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Grade 4 TMI Toxicity</measure>
    <time_frame>1 year post-transplant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With 1 Year Mortality Unrelated to TMI</measure>
    <time_frame>1 year post-transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Neutrophil and Platelet Engraftment in Patients With Hematologic Malignancies</measure>
    <time_frame>Up to 100 days post-transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Lymphoblastic Leukemia</condition>
  <condition>Acute Leukemia</condition>
  <condition>Non Hodgkins Lymphoma</condition>
  <condition>Chronic Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>IM-TMI (3Gy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 3Gy per day for 1 day (total of 3Gy).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IM-TMI (6Gy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 3Gy per day for 2 days (for a total of 6Gy).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IM-TMI (9Gy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 3Gy per day for 3 days (for a total of 9Gy).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IM-TMI (12Gy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 3Gy per day for 4 days (for a total of 12Gy).</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IM-TMI (3Gy)</intervention_name>
    <description>Patients will receive 3Gy per day for 1 day.</description>
    <arm_group_label>IM-TMI (3Gy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IM-TMI (6Gy)</intervention_name>
    <description>Patients will receive 3Gy per day for 2 days.</description>
    <arm_group_label>IM-TMI (6Gy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IM-TMI (9Gy)</intervention_name>
    <description>Patients will receive 3Gy per day for 3 days.</description>
    <arm_group_label>IM-TMI (9Gy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IM-TMI (12Gy)</intervention_name>
    <description>Patients will receive 3Gy per day for 4 days.</description>
    <arm_group_label>IM-TMI (12Gy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with the following diseases:&#xD;
&#xD;
               -  Acute myeloid or lymphoblastic leukemia in first complete remission if poor&#xD;
                  prognosis documented by failure to response after initial induction chemotherapy,&#xD;
                  or cytogenetic, or molecular studies.&#xD;
&#xD;
               -  Acute leukemia in greater/equal second remission, or partial remission after&#xD;
                  chemotherapy.&#xD;
&#xD;
               -  High grade non Hodgkin's or Hodgkin's lymphoma with marrow involvement resistant/&#xD;
                  relapsed after second line therapy including high dose chemotherapy and&#xD;
                  autologous SCT.&#xD;
&#xD;
               -  CML in advanced or blastic phase.&#xD;
&#xD;
               -  Plasma cell leukemia.&#xD;
&#xD;
          -  Age 18-60 years.&#xD;
&#xD;
          -  Karnofsky performance status of 70&#xD;
&#xD;
          -  Adequate cardiac and pulmonary function. Patients with decreased LVEF less than/equal&#xD;
             to 40% or DLCO less than/equal to 50% of predicted will require clearance from&#xD;
             cardiology or pulmonary services, respectively, prior to enrollment on this protocol.&#xD;
&#xD;
          -  Serum creatinine less than/equal to 1.5 mg/dL or Creatinine Clearance greater&#xD;
             than/equal to 50 ml/min .&#xD;
&#xD;
          -  Serum bilirubin 2.0 mg/dl, SGPT less than/equal to 3 times the upper limit of normal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Life expectancy is severely limited by concomitant illness.&#xD;
&#xD;
          -  Evidence of chronic active hepatitis or cirrhosis&#xD;
&#xD;
          -  HIV-positive&#xD;
&#xD;
          -  Patient is pregnant&#xD;
&#xD;
          -  Patient or guardian is not able to sign informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Damiano Rondelli, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 30, 2009</study_first_submitted>
  <study_first_submitted_qc>September 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2009</study_first_posted>
  <results_first_submitted>April 21, 2021</results_first_submitted>
  <results_first_submitted_qc>May 18, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 14, 2021</results_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Chicago</investigator_affiliation>
    <investigator_full_name>Damiano Rondelli, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>total marrow irradiation</keyword>
  <keyword>intensity modulated radiation</keyword>
  <keyword>leukemia</keyword>
  <keyword>hematologic diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>IM-TMI (3Gy)</title>
          <description>Patients will receive 3Gy per day for 1 day (total of 3Gy).&#xD;
IM-TMI (3Gy): Patients will receive 3Gy per day for 1 day.</description>
        </group>
        <group group_id="P2">
          <title>IM-TMI (6Gy)</title>
          <description>Patients will receive 3Gy per day for 2 days (for a total of 6Gy).&#xD;
IM-TMI (6Gy): Patients will receive 3Gy per day for 2 days.</description>
        </group>
        <group group_id="P3">
          <title>IM-TMI (9Gy)</title>
          <description>Patients will receive 3Gy per day for 3 days (for a total of 9Gy).&#xD;
IM-TMI (9Gy): Patients will receive 3Gy per day for 3 days.</description>
        </group>
        <group group_id="P4">
          <title>IM-TMI (12Gy)</title>
          <description>Patients will receive 3Gy per day for 4 days (for a total of 12Gy).&#xD;
IM-TMI (12Gy): Patients will receive 3Gy per day for 4 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IM-TMI (3Gy)</title>
          <description>Patients will receive 3Gy per day for 1 day (total of 3Gy).&#xD;
IM-TMI (3Gy): Patients will receive 3Gy per day for 1 day.</description>
        </group>
        <group group_id="B2">
          <title>IM-TMI (6Gy)</title>
          <description>Patients will receive 3Gy per day for 2 days (for a total of 6Gy).&#xD;
IM-TMI (6Gy): Patients will receive 3Gy per day for 2 days.</description>
        </group>
        <group group_id="B3">
          <title>IM-TMI (9Gy)</title>
          <description>Patients will receive 3Gy per day for 3 days (for a total of 9Gy).&#xD;
IM-TMI (9Gy): Patients will receive 3Gy per day for 3 days.</description>
        </group>
        <group group_id="B4">
          <title>IM-TMI (12Gy)</title>
          <description>Patients will receive 3Gy per day for 4 days (for a total of 12Gy).&#xD;
IM-TMI (12Gy): Patients will receive 3Gy per day for 4 days.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="2"/>
            <count group_id="B5" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" lower_limit="52" upper_limit="63"/>
                    <measurement group_id="B2" value="38" lower_limit="38" upper_limit="52"/>
                    <measurement group_id="B3" value="39" lower_limit="20" upper_limit="65"/>
                    <measurement group_id="B4" value="53" lower_limit="53" upper_limit="62"/>
                    <measurement group_id="B5" value="52" lower_limit="20" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Grade 4 TMI Toxicity</title>
        <time_frame>1 year post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IM-TMI (3Gy)</title>
            <description>Patients will receive 3Gy per day for 1 day (total of 3Gy).&#xD;
IM-TMI (3Gy): Patients will receive 3Gy per day for 1 day.</description>
          </group>
          <group group_id="O2">
            <title>IM-TMI (6Gy)</title>
            <description>Patients will receive 3Gy per day for 2 days (for a total of 6Gy).&#xD;
IM-TMI (6Gy): Patients will receive 3Gy per day for 2 days.</description>
          </group>
          <group group_id="O3">
            <title>IM-TMI (12Gy)</title>
            <description>Patients will receive 3Gy per day for 3 days (for a total of 12Gy).&#xD;
IM-TMI (9Gy): Patients will receive 3Gy per day for 3 days.</description>
          </group>
          <group group_id="O4">
            <title>IM-TMI (9Gy)</title>
            <description>Patients will receive 3Gy per day for 4 days (for a total of 9Gy).&#xD;
IM-TMI (12Gy): Patients will receive 3Gy per day for 4 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Grade 4 TMI Toxicity</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Neutrophil and Platelet Engraftment in Patients With Hematologic Malignancies</title>
        <time_frame>Up to 100 days post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IM-TMI (3Gy)</title>
            <description>Patients will receive 3Gy per day for 1 day (total of 3Gy).&#xD;
IM-TMI (3Gy): Patients will receive 3Gy per day for 1 day.</description>
          </group>
          <group group_id="O2">
            <title>IM-TMI (6Gy)</title>
            <description>Patients will receive 3Gy per day for 2 days (for a total of 6Gy).&#xD;
IM-TMI (6Gy): Patients will receive 3Gy per day for 2 days.</description>
          </group>
          <group group_id="O3">
            <title>IM-TMI (9Gy)</title>
            <description>Patients will receive 3Gy per day for 3 days (for a total of 9Gy).&#xD;
IM-TMI (9Gy): Patients will receive 3Gy per day for 3 days.</description>
          </group>
          <group group_id="O4">
            <title>IM-TMI (12Gy)</title>
            <description>Patients will receive 3Gy per day for 4 days (for a total of 12Gy).&#xD;
IM-TMI (12Gy): Patients will receive 3Gy per day for 4 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Neutrophil and Platelet Engraftment in Patients With Hematologic Malignancies</title>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="10" upper_limit="20"/>
                    <measurement group_id="O2" value="15" lower_limit="10" upper_limit="20"/>
                    <measurement group_id="O3" value="15" lower_limit="10" upper_limit="20"/>
                    <measurement group_id="O4" value="15" lower_limit="10" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With 1 Year Mortality Unrelated to TMI</title>
        <time_frame>1 year post-transplant</time_frame>
        <population>Grade 4 TMI toxicity 0 Grade 4 TMI toxicity 0 Grade 4 TMI toxicity 0 Grade 4 TMI toxicity 0</population>
        <group_list>
          <group group_id="O1">
            <title>IM-TMI (3Gy)</title>
            <description>Patients will receive 3Gy per day for 1 day (total of 3Gy).&#xD;
IM-TMI (3Gy): Patients will receive 3Gy per day for 1 day.</description>
          </group>
          <group group_id="O2">
            <title>IM-TMI (6Gy)</title>
            <description>Patients will receive 3Gy per day for 2 days (for a total of 6Gy).&#xD;
IM-TMI (6Gy): Patients will receive 3Gy per day for 2 days.</description>
          </group>
          <group group_id="O3">
            <title>IM-TMI (9Gy)</title>
            <description>Patients will receive 3Gy per day for 3 days (for a total of 9Gy).&#xD;
IM-TMI (9Gy): Patients will receive 3Gy per day for 3 days.</description>
          </group>
          <group group_id="O4">
            <title>IM-TMI (12Gy)</title>
            <description>Patients will receive 3Gy per day for 4 days (for a total of 12Gy).&#xD;
IM-TMI (12Gy): Patients will receive 3Gy per day for 4 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With 1 Year Mortality Unrelated to TMI</title>
          <population>Grade 4 TMI toxicity 0 Grade 4 TMI toxicity 0 Grade 4 TMI toxicity 0 Grade 4 TMI toxicity 0</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>IM-TMI (3Gy)</title>
          <description>Patients will receive 3Gy per day for 1 day (total of 3Gy).&#xD;
IM-TMI (3Gy): Patients will receive 3Gy per day for 1 day.</description>
        </group>
        <group group_id="E2">
          <title>IM-TMI (6Gy)</title>
          <description>Patients will receive 3Gy per day for 2 days (for a total of 6Gy).&#xD;
IM-TMI (6Gy): Patients will receive 3Gy per day for 2 days.</description>
        </group>
        <group group_id="E3">
          <title>IM-TMI (9Gy)</title>
          <description>Patients will receive 3Gy per day for 3 days (for a total of 9Gy).&#xD;
IM-TMI (9Gy): Patients will receive 3Gy per day for 3 days.</description>
        </group>
        <group group_id="E4">
          <title>IM-TMI (12Gy)</title>
          <description>Patients will receive 3Gy per day for 4 days (for a total of 12Gy).&#xD;
IM-TMI (12Gy): Patients will receive 3Gy per day for 4 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>GVHD</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gut mucocitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Oral mucositis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Damiano Rondelli</name_or_title>
      <organization>University of Illinois at Chicago</organization>
      <phone>312-996-6179</phone>
      <email>drond@uic.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

